Cardiac Pathways Receives CE Mark for Its Radii-T Mapping and Ablation Catheters for Treating Irregular Heart Rhythms.SUNNYVALE, Calif.--(BW HealthWire)--April 30, 1998--Cardiac Pathways Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CPWY), a developer of minimally invasive, cost-effective systems for diagnosing and treating abnormally rapid heart rhythms, today announced that it has received the CE mark for its Radii-T(r) mapping and ablation catheters used to treat supraventricular tachycardia supraventricular tachycardia n. Abbr. SVT A tachycardia that originates above the ventricles of the heart, as in the atria or the atrioventricular node. (SVT SVT supraventricular tachycardia. SVT abbr. supraventricular tachycardia SVT Supraventricular tachycardia, see there ), allowing the product to be sold throughout the European Community European Community: see European Union. European Community (EC) Organization formed in 1967 with the merger of the European Economic Community, European Coal and Steel Community, and European Atomic Energy Community. . The Radii-T catheter is a disposable, steerable device, which facilitates the mapping, or diagnosis, of cardiac arrhythmias. The tip of the Radii-T catheter has an electrode that contains a temperature sensor, allowing the physician to measure the temperature for ablation of the cardiac arrhythmias. Having the ability to monitor catheter temperature at the tip during ablation guides the physician in avoiding problematic heat build up which could otherwise limit the effectiveness of the procedure. The Radii-T catheters are available in two versions, one with a thermocouple designed for RF generators that require thermocouple temperature-sensing, and one with a thermistor Thermistor An electrical resistor with a relatively large negative temperature coefficient of resistance. Thermistors are useful for measuring temperature and gas flow or wind velocity. designed for RF generators that require thermistor temperature-sensing. Company president and chief executive officer, William Starling starling, any of a group of originally Old World birds that have become distributed worldwide. Starlings were brought to New York in 1890; since then the common starling (Sturnus vulgaris) has spread throughout North America. , stated, "Receiving the CE mark for the Radii-T complements our receipt of the CE mark for our Chilli(r) catheter earlier this year. Cardiac Pathways is the only company that has obtained CE marks in Europe for both SVT and ventricular tachycardia Ventricular Tachycardia Definition Ventricular tachycardia (V-tach) is a rapid heart beat that originates in one of the lower chambers (the ventricles) of the heart. (VT) devices. This is very important to our continued success in expanding our marketing efforts of a complete product line in the European community." Cardiac Pathways designs, develops and manufactures minimally invasive systems to diagnose and treat cardiac tachyarrhythmias (abnormally rapid heart rhythms). The Company is a pioneer and leader in the development of complete, integrated mapping and ablation systems for the diagnosis and treatment of ventricular tachycardia and atrial fibrillation atrial fibrillation Irregular rhythm (arrhythmia) of contraction of the atria (upper heart chambers). The most common major arrhythmia, it may result as a consequence of increased fibrous tissue in the aging heart, of heart disease, or in association with severe infection. , two of the most serious and prevalent types of heart rhythm disturbances. This release contains certain forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the progress of the Company's actions relating to regulatory matters, marketing and sales activities, particularly in Europe, the extent to which the Company's products gain market acceptance, particularly in Europe, and competitive developments. CONTACT: Cardiac Pathways Corporation David W. Gryska, 408-737-0505 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion